Phase III Study of AZD7442 for Treatment of COVID-19 in Outpatient Adults

PHASE3CompletedINTERVENTIONAL
Enrollment

910

Participants

Timeline

Start Date

January 28, 2021

Primary Completion Date

August 21, 2021

Study Completion Date

October 19, 2022

Conditions
COVID-19
Interventions
DRUG

AZD7442

Single dose (× 2 separate IM injections) of 600 mg of AZD7442 or saline placebo on Day 1.

DRUG

Placebo

Single dose (× 2 separate IM injections) of 600 mg of AZD7442 or saline placebo on Day 1.

Trial Locations (103)

3200

Research Site, Gyöngyös

4031

Research Site, Debrecen

10016

Research Site, New York

10243

Research Site, Friedrichshain

10439

Research Site, Berlin

10777

Research Site, Berlin

14050

Research Site, Tlalpan

14080

Research Site, Tlalpan

14940

Research Site, Cabra

15088

Research Site, Lima

17005

Research Site, Girona

20095

Research Site, Hamburg

20127

Research Site, Milan

28031

Research Site, Madrid

28208

Research Site, Charlotte

28277

Research Site, Charlotte

28625

Research Site, Statesville

29010

Research Site, Málaga

29121

Research Site, Piacenza

29169

Research Site, West Columbia

30625

Research Site, Hanover

31350

Research Site, Chihuahua City

33064

Research Site, Pompano Beach

33125

Research Site, Miami

33157

Research Site, Cutler Bay

33165

Research Site, Miami

35501

Research Site, Jasper

42016

Research Site, Guastalla

43213

Research Site, Columbus

44100

Research Site, Guadalajara

44200

Research Site, Guadalajara

49102

Research Site, Dnipro

50668

Research Site, Cologne

54750

Research Site, Cuautitlán Izcalli

55128

Research Site, Mainz

55450

Research Site, Ecatepec de Morelos

56068

Research Site, Koblenz

56124

Research Site, Pisa

58104

Research Site, Fargo

60389

Research Site, Frankfurt am Main

60596

Research Site, Frankfurt

60621

Research Site, Chicago

63141

Research Site, St Louis

64460

Research Site, Monterrey

68128

Research Site, La Vista

70601

Research Site, Lake Charles

73000

Research Site, Kherson

75235

Research Site, Dallas

77027

Research Site, Houston

77057

Research Site, Houston

77093

Research Site, Houston

77338

Research Site, Humble

78018

Research Site, Ivano-Frankivsk

80336

Research Site, München

81241

Research Site, München-Pasing

82110

Research Site, Mazatlán

85704

Research Site, Tucson

90806

Research Site, Long Beach

91324

Research Site, Northridge

97070

Research Site, Mérida

143442

Research Site, Moscow

183047

Research Site, Murmansk

192283

Research Site, Saint Petersburg

196084

Research Site, Saint Petersburg

197227

Research Site, Saint Petersburg

199106

Research Site, Saint Petersburg

199226

Research Site, Saint Petersburg

B7600FYW

Research Site, Buenos Aires

C1039

Research Site, Buenos Aires

C1430EGF

Research Site, Buenos Aires

B1605FRE

Research Site, Munro

89030-101

Research Site, Blumenau

90430-001

Research Site, Porto Alegre

14051-140

Research Site, Ribeirão Preto

01228-200

Research Site, São Paulo

18040-425

Research Site, Sorocaba

500 02

Research Site, Hradec Králové

280 02

Research Site, Kolín

568 25

Research Site, Svitavy

00149

Research Site, Roma

260-0852

Research Site, Chiba

193-0998

Research Site, Hachioji-shi

350-0495

Research Site, Iruma-Gun

607-8062

Research Site, Kyoto

371-0811

Research Site, Maebashi

286-8520

Research Site, Narita-shi

983-8512

Research Site, Sendai

140-8522

Research Site, Shinagawa-ku

142-8666

Research Site, Shinagawa-ku

162-8655

Research Site, Shinjuku-ku

06700

Research Site, Cuauhtémoc

35-326

Research Site, Rzeszów

05-200

Research Site, Wołomin

08540

Research Site, Centelles (Barcelona)

FY3 7EN

Research Site, Blackpool

RG12 8WY

Research Site, Bracknell

BS8 2PU

Research Site, Bristol

CB2 2QQ

Research Site, Cambridge

TR27 5DT

Research Site, Connor Downs

N19 5NF

Research Site, Highgate

LE5 4LJ

Research Site, Leicester

PR2 9HT

Research Site, Preston

OL11 4AU

Research Site, Rochdale

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY